Continuous	continuous	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
prevent	prevent	O	O	O	O
ifosfamide-induced	ifosfamide-induced	O	O	O	O
hemorrhagic	hemorrhagic	O	DISEASE	OTHERS	I
cystitis	cystitis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Hemorrhagic	hemorrhagic	O	DISEASE	OTHERS	I
cystitis	cystitis	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
potential	potential	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
that	that	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
prevented	prevented	O	O	O	O
by	by	O	O	O	O
administering	administering	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
along	along	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
cytotoxic	cytotoxic	O	O	O	O
agent	agent	O	O	O	O
.	.	O	O	O	O

Mesna	mesna	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
generally	generally	O	O	O	O
administered	administered	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
intravenous	intravenous	O	O	O	O
route	route	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
experience	experience	O	O	O	O
with	with	O	O	O	O
oral	oral	O	O	O	O
delivery	delivery	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
has	has	O	O	O	O
increased	increased	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
continuous	continuous	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
the	the	O	O	O	O
advantage	advantage	O	O	O	O
of	of	O	O	O	O
not	not	O	O	O	O
requiring	requiring	O	O	O	O
intravenous	intravenous	O	O	O	O
access	access	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
,	,	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
delivery	delivery	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
neutralizing	neutralizing	O	O	O	O
agent	agent	O	O	O	O
will	will	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
inadequate	inadequate	O	O	O	O
urinary	urinary	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
concentrations	concentrations	O	O	O	O
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
taking	taking	O	O	O	O
oral	oral	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
who	who	O	O	O	O
experiences	experiences	O	O	O	O
severe	severe	O	O	O	O
ifosfamide-induced	ifosfamide-induced	O	O	O	O
emesis	emesis	O	O	OTHERS	I
and	and	O	O	O	O
is	is	O	O	O	O
unable	unable	O	O	O	O
to	to	O	O	O	O
absorb	absorb	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

Limited	limited	O	O	O	O
clinical	clinical	O	O	O	O
experience	experience	O	O	O	O
with	with	O	O	O	O
continuous	continuous	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
suggests	suggests	O	O	O	O
it	it	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
safe	safe	O	O	O	O
,	,	O	O	O	O
practical	practical	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
economic	economic	O	O	O	O
method	method	O	O	O	O
of	of	O	O	O	O
drug	drug	O	O	O	O
delivery	delivery	O	O	O	O
that	that	O	O	O	O
permits	permits	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
be	be	O	O	O	O
administered	administered	O	O	O	O
successfully	successfully	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
outpatient	outpatient	O	O	O	O
setting	setting	O	O	O	O
.	.	O	O	O	O

